Imperial College London Featured PhD Programmes
Gdansk University of Technology Featured PhD Programmes
University of Reading Featured PhD Programmes

myeloma PhD Projects, Programmes & Scholarships

We have 9 myeloma PhD Projects, Programmes & Scholarships

Discipline

Discipline

All disciplines

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


We have 9 myeloma PhD Projects, Programmes & Scholarships

PhD saved successfully

Validation of TRAF6/PD-L1 inhibition in pre-clinical models of multiple myeloma: implications for combinational immunotherapy

Programmed death-ligand 1(PD-L1), a negative regulator of the immune system, is highly expressed in newly-diagnosed and relapsed multiple myeloma patients, and its expression is associated with suppressed anti-tumour immunity. Read more

Role of tumour directed T cells in smouldering myeloma

The UCL Myeloma and Tumour Immunology groups are seeking a talented and enthusiastic PhD candidate to lead a project to identify and characterise tumour directed T cells in the bone marrow environment of patients with smouldering myeloma. Smouldering myeloma is a pre-cancerous condition that carries a 50% risk (over 5 years) of developing into the bone marrow cancer called multiple myeloma. Read more

An interdisciplinary approach to tackling the problem of late Myeloma diagnosis.

There are two parallel studentships on offer. One (this project) is a wet lab project and the other is a bioinformatics project. Both are addressing the fact that multiple myeloma (MM) (a blood cancer of antibody producing cells) is nearly always diagnosed late. Read more

Metabolic reprogramming in cancer: starving tumors of essential nutrients to promote cell death

All the cells in our bodies are programmed to die. As they get older, our cells accumulate toxic molecules that make them sick. In response, they eventually break down and die, clearing the way for new, healthy cells to grow. Read more

Macrophage driven therapy resistance in AML: from macrophage subset characterisation to therapeutic targeting.

  Research Group: Molecular Mechanisms and Long Term Conditions
Reference. SHLS20065. Background. Acute Myeloid Leukaemia (AML) is a common blood cancer in adults; with its incidence increasing with age, AML cases are predicted to double by 2030. Read more
  • 1

Filtering Results